Additional studies are needed to define the mechanism by which methylation at these residues could affect TSC disease pathology and whether activation or inhibition of PRMT1 could be an effective strategy to mitigate the symptoms of TSC disease. This evidence concerns the gene PRMT1 and tuberous sclerosis.